James Howard, MD
Retina Specialist · Salt Lake City, UTNPI 1033110119
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,165 of the $14,246 with a category attached, or 64.3%. Genentech USA, Inc. accounts for 75.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $7,876 and has fallen 96.0% since, to $313 in 2025.
Across 86 payments — averaging $165.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$11K
- US Retina LLC$2K
- Regeneron Healthcare Solutions, Inc.$473
- Genentech, Inc.$274
- Astellas Pharma US Inc$182
- Regeneron$117
- plus $261 from 5 others
Across 205 payments — averaging $13,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.2M
- Ocular Therapeutix, Inc.$527K
- Apellis Pharmaceuticals, Inc.$50K
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$9,16564%
- Travel & lodging$7815%
- Food & beverage$2,11615%
- Ownership interest$2,18515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 35 | $10,755 |
| US Retina LLC | 6 | $2,185 |
| Regeneron Healthcare Solutions, Inc. | 17 | $473 |
| Genentech, Inc. | 8 | $274 |
| Astellas Pharma US Inc | 8 | $182 |
| Regeneron | 1 | $117 |
| Apellis Pharmaceuticals, Inc. | 3 | $91 |
| Ocular Therapeutix, Inc. | 3 | $80 |
| Biogen | 3 | $55 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,246 in reported general payments places this provider in the 85th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 113 | $4,243 |
| MoxifloxacinMoxifloxacin Hcl | 74 | $1,643 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,426 |
| Ketorolac Tromethamine | 35 | $877 |
| Latanoprost | 64 | $480 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $423 |
| Timolol Maleate | 34 | $254 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $190 |
| Brimonidine Tartrate | 15 | $121 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Salt Lake City
- Robert KwunSalt Lake City$334K
- Mitchell GoffSalt Lake City$165K
- David FaberSalt Lake City$10K
- Rebekah GensureSalt Lake City$5K
- Kirk WinwardSalt Lake City$3K
- Eric BrintonSalt Lake City$3K
- Gregory BrintonSalt Lake City$1K
- Mano SwartzSalt Lake City$28
- Andrew DavisWest Jordan$4K
- Joshua CarlsonSt George$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.